SAGE Therapeutics Inc (NASDAQ:SAGE) – Research analysts at SunTrust Banks increased their FY2018 earnings per share estimates for SAGE Therapeutics in a research report issued on Tuesday, November 6th. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings of ($7.45) per share for the year, up from their previous estimate of ($7.55). SunTrust Banks also issued estimates for SAGE Therapeutics’ Q4 2018 earnings at ($2.76) EPS, Q1 2019 earnings at ($2.87) EPS, Q2 2019 earnings at ($2.88) EPS, Q3 2019 earnings at ($2.88) EPS, Q4 2019 earnings at ($2.83) EPS, FY2019 earnings at ($11.46) EPS, FY2020 earnings at ($8.60) EPS, FY2021 earnings at ($5.36) EPS and FY2022 earnings at $1.45 EPS.

A number of other research firms have also weighed in on SAGE. BidaskClub upgraded SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 18th. Piper Jaffray Companies started coverage on SAGE Therapeutics in a report on Monday, August 6th. They set an “overweight” rating and a $206.00 target price for the company. Stifel Nicolaus upped their target price on SAGE Therapeutics from $198.00 to $239.00 and gave the stock a “buy” rating in a report on Tuesday, August 7th. Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, Oppenheimer started coverage on SAGE Therapeutics in a report on Wednesday, October 10th. They set a “buy” rating and a $170.00 target price for the company. One investment analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $208.33.

Shares of NASDAQ SAGE opened at $130.94 on Friday. The company has a market capitalization of $6.09 billion, a P/E ratio of -18.47 and a beta of 2.76. SAGE Therapeutics has a 52-week low of $83.00 and a 52-week high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.41) by ($0.22). During the same quarter in the previous year, the firm posted ($1.97) earnings per share.

A number of institutional investors have recently bought and sold shares of the business. CIBC Asset Management Inc increased its position in shares of SAGE Therapeutics by 26.4% during the second quarter. CIBC Asset Management Inc now owns 1,633 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 341 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of SAGE Therapeutics by 3.2% during the first quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock worth $1,998,000 after purchasing an additional 382 shares in the last quarter. BTG Pactual Global Asset Management Ltd increased its position in shares of SAGE Therapeutics by 12.4% during the second quarter. BTG Pactual Global Asset Management Ltd now owns 4,015 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 442 shares in the last quarter. CIBC World Markets Inc. increased its position in shares of SAGE Therapeutics by 16.3% during the second quarter. CIBC World Markets Inc. now owns 4,130 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 580 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of SAGE Therapeutics by 3.7% during the first quarter. Legal & General Group Plc now owns 17,581 shares of the biopharmaceutical company’s stock worth $2,831,000 after purchasing an additional 629 shares in the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: Price to Earnings Ratio (PE) Basics

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.